BMT Update: Bortezomib in a conditioning regimen for auto transplant in multiple myeloma
Bortezomib is being used in a conditioning regimen for auto transplant in multiple myeloma. It is combined with high dose melphalan which is given as an inpatient (U57). This is based on the French study published in Blood. 7 Jan 2010. Volume 115:1. 32-37.
Bortezomib is given day -5, -2, which may be given as an out patient (TBCC), followed the remainder of the protocol given on U57 as an inpatient (melphalan day -1 and velcade day 1 and 4).
0 comments:
Post a Comment